Palliative and Advanced Illness Research (PAIR) Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Division of Pulmonary, Allergy and Critical Care, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Crit Care Med. 2019 Mar;47(3):e198-e205. doi: 10.1097/CCM.0000000000003617.
Despite strong evidence supporting proning in acute respiratory distress syndrome, few eligible patients receive it. This study determines the cost-effectiveness of interventions to increase utilization of proning for severe acute respiratory distress syndrome.
We created decision trees to model severe acute respiratory distress syndrome from ICU admission through death (societal perspective) and hospital discharge (hospital perspective). We assumed patients received low tidal volume ventilation. We used short-term outcome estimates from the PROSEVA trial and longitudinal cost and benefit data from cohort studies. In probabilistic sensitivity analyses, we used distributions for each input that included the fifth to 95th percentile of its CI.
ICUs that care for patients with acute respiratory distress syndrome.
Patients with moderate to severe acute respiratory distress syndrome.
The implementation of a hypothetical intervention to increase the appropriate utilization of prone positioning.
In the societal perspective model, an intervention that increased proning utilization from 16% to 65% yielded an additional 0.779 (95% CI, 0.088-1.714) quality-adjusted life years at an additional long-term cost of $31,156 (95% CI, -$158 to $92,179) (incremental cost-effectiveness ratio = $38,648 per quality-adjusted life year [95% CI, $1,695-$98,522]). If society was willing to pay $100,000 per quality-adjusted life year, any intervention costing less than $51,328 per patient with moderate to severe acute respiratory distress syndrome would represent good value. From a hospital perspective, the intervention yielded 0.072 (95% CI, 0.008-0.147) more survivals-to-discharge at a cost of $5,242 (95% CI, -$19,035 to $41,019) (incremental cost-effectiveness ratio = $44,615 per extra survival [95% CI, -$250,912 to $558,222]). If hospitals were willing to pay $100,000 per survival-to-discharge, any intervention costing less than $5,140 per patient would represent good value.
Interventions that increase utilization of proning would be cost-effective from both societal and hospital perspectives under many plausible cost and benefit assumptions.
尽管有强有力的证据支持急性呼吸窘迫综合征患者接受俯卧位通气,但只有少数符合条件的患者接受了该治疗。本研究旨在评估增加俯卧位通气应用的干预措施在治疗严重急性呼吸窘迫综合征方面的成本效益。
我们构建决策树,从 ICU 入院到死亡(社会视角)和出院(医院视角)两个方面对严重急性呼吸窘迫综合征患者进行建模。假设患者接受低潮气量通气。我们使用 PROSEVA 试验的短期结局估计值和队列研究的纵向成本和获益数据。在概率敏感性分析中,我们使用包含第 5 至 95 个百分位区间的分布来表示每个输入的分布。
收治急性呼吸窘迫综合征患者的 ICU。
中重度急性呼吸窘迫综合征患者。
实施增加俯卧位通气应用的假设性干预措施。
在社会视角模型中,将俯卧位通气使用率从 16%提高到 65%,可使长期成本增加 31,156 美元(95%CI,-158 美元至 92,179 美元),并额外获得 0.779 个质量调整生命年(95%CI,0.088-1.714)(增量成本效益比=38,648 美元/质量调整生命年[95%CI,1695 美元至 98,522 美元])。如果社会愿意为每个质量调整生命年支付 10 万美元,那么对于中度至重度急性呼吸窘迫综合征患者,任何成本低于 51,328 美元/人的干预措施都具有良好的价值。从医院的角度来看,该干预措施可使出院存活率增加 0.072(95%CI,0.008-0.147),但成本增加 5,242 美元(95%CI,-19,035 美元至 41,019 美元)(增量成本效益比=44,615 美元/额外存活者[95%CI,-250,912 美元至 558,222 美元])。如果医院愿意为每个出院存活率支付 10 万美元,那么任何成本低于 5,140 美元/人的干预措施都具有良好的价值。
在许多成本和获益假设下,从社会和医院角度来看,增加俯卧位通气使用率的干预措施具有成本效益。